Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

Iovance Biotherapeutics (IOVA) will host a webcast on October 29, 2026 to discuss lung cancer therapy results and precision medicine opportunities.

Rhea-AI Summary

Iovance Biotherapeutics (IOVA) will host a webcast on October 29, 2026 to discuss lung cancer therapy results and precision medicine opportunities.

The call begins at 8:30 a.m. ET. Iovance describes the results for one-time lifileucel as positive, from IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous metastatic non-small cell lung cancer. The discussion will also cover precision-based medicine opportunities for its tumor infiltrating lymphocyte therapy platform.

Argus 15 min delay 46 alerts

+12.42% vs previous close $16.65 last price 0.8x rel. volume Open Argus

Details

Market move: IOVA +12.42% vs previous close. Phase 2 clinical data

+13.8% Peak in 14 min

$14.18 – $17.62 Day Range

$7.54B Mkt Cap at Last Price

On Oct 28, the day this news came out, the latest delayed price for IOVA is 12.42% above the previous close. Argus tracked a peak move of +13.8% during the session. Our momentum scanner has recorded 46 alerts for this stock so far that day. The latest delayed price is $16.65.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

polyclonal, tumor infiltrating lymphocyte, mNSCLC

3 terms

polyclonal medical

"polyclonal tumor infiltrating lymphocyte (TIL) therapies"

Polyclonal describes a mixture of antibodies or immune cells that all recognize the same target but come from many different immune-cell sources, like a crowd of people each noticing a different detail of the same object. For investors, polyclonal products and tests are often more forgiving when targets change, yet they can be harder to standardize, scale and regulate than single-source (monoclonal) alternatives, affecting manufacturing consistency, cost and regulatory risk.

tumor infiltrating lymphocyte medical

"polyclonal tumor infiltrating lymphocyte (TIL) therapies"

Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.

mNSCLC medical

"previously treated nonsquamous mNSCLC"

mNSCLC stands for metastatic non-small cell lung cancer, meaning lung cancer from the non-small cell group (most commonly adenocarcinoma, squamous cell, or large‑cell types) that has spread beyond the original lung site to other parts of the body. “Metastatic” indicates advanced disease (typically stage IV) and is diagnosed by imaging and pathology; treatment and clinical-trial eligibility often depend on tumor histology and molecular biomarkers rather than on the original localized therapies used for early-stage disease.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, October 29, 2026 at 8:30 a.m. ET to highlight positive results for one-time lifileucel TIL therapy from the IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous mNSCLC and an update on precision-based medicine opportunities for the TIL platform in mNSCLC.

To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/qtiiq5pi. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi^® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150